Trial Profile
A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 21 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jan 2029.
- 17 Jun 2022 Updated results (as of 14 Feb 2022) reporting long-term safety and efficacy with median follow-up now of over 41 months presented at the 27th Congress of the European Haematology Association
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association